Management of hepatitis B and C virus infection before and after renal transplantation

Fabrizio Fabrizi, Paul Martin

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: The management of hepatitis B and C-related liver disease in patients with chronic kidney disease remains an area of controversy. The availability of novel antiviral agents has allowed the implementation of numerous trials concerning the treatment of hepatitis before and after renal transplantation. RECENT FINDINGS: Long-term trials with lamivudine for chronic hepatitis B infections after renal transplantation have shown durable suppression of hepatitis B viraemia ranging between 43 and 78%; however, the 3-4 year cumulative probability of developing lamivudine resistance is approximately 60%. Lamivudine-resistant strains have led to hepatic decompensation in several renal transplant recipients. The sustained virological response rate after interferon monotherapy in dialysis patients with chronic hepatitis C is approximately 40%, but tolerance to interferon monotherapy is poor, and its use is contraindicated after renal transplantation because of acute graft dysfunction. Encouraging sustained virological responses have been obtained after combined therapy (interferon plus ribavirin) in dialysis patients, but the appropriate ribavirin dose remains to be assessed. Only preliminary information exists on the use of pegylated interferon in end-stage renal disease. SUMMARY: This review summarizes recent and novel advances in the antiviral treatment of hepatitis B and C in dialysis patients and renal transplant recipients.

Original languageEnglish
Pages (from-to)583-588
Number of pages6
JournalCurrent Opinion in Organ Transplantation
Volume11
Issue number6
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Virus Diseases
Hepatitis B virus
Hepacivirus
Kidney Transplantation
Interferons
Lamivudine
Hepatitis B
Ribavirin
Hepatitis C
Antiviral Agents
Dialysis
Viremia
Chronic Hepatitis B
Chronic Hepatitis C
Chronic Renal Insufficiency
Hepatitis
Chronic Kidney Failure
Renal Dialysis
Liver Diseases
Therapeutics

Keywords

  • Interferon
  • Lamivudine
  • Renal transplantation
  • Ribavirin
  • Sustained virological response

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Management of hepatitis B and C virus infection before and after renal transplantation. / Fabrizi, Fabrizio; Martin, Paul.

In: Current Opinion in Organ Transplantation, Vol. 11, No. 6, 01.12.2006, p. 583-588.

Research output: Contribution to journalArticle

@article{d6790d5cff7d45d392b9e533bc6c4bd0,
title = "Management of hepatitis B and C virus infection before and after renal transplantation",
abstract = "PURPOSE OF REVIEW: The management of hepatitis B and C-related liver disease in patients with chronic kidney disease remains an area of controversy. The availability of novel antiviral agents has allowed the implementation of numerous trials concerning the treatment of hepatitis before and after renal transplantation. RECENT FINDINGS: Long-term trials with lamivudine for chronic hepatitis B infections after renal transplantation have shown durable suppression of hepatitis B viraemia ranging between 43 and 78{\%}; however, the 3-4 year cumulative probability of developing lamivudine resistance is approximately 60{\%}. Lamivudine-resistant strains have led to hepatic decompensation in several renal transplant recipients. The sustained virological response rate after interferon monotherapy in dialysis patients with chronic hepatitis C is approximately 40{\%}, but tolerance to interferon monotherapy is poor, and its use is contraindicated after renal transplantation because of acute graft dysfunction. Encouraging sustained virological responses have been obtained after combined therapy (interferon plus ribavirin) in dialysis patients, but the appropriate ribavirin dose remains to be assessed. Only preliminary information exists on the use of pegylated interferon in end-stage renal disease. SUMMARY: This review summarizes recent and novel advances in the antiviral treatment of hepatitis B and C in dialysis patients and renal transplant recipients.",
keywords = "Interferon, Lamivudine, Renal transplantation, Ribavirin, Sustained virological response",
author = "Fabrizio Fabrizi and Paul Martin",
year = "2006",
month = "12",
day = "1",
doi = "10.1097/MOT.0b013e3280105c5c",
language = "English",
volume = "11",
pages = "583--588",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Management of hepatitis B and C virus infection before and after renal transplantation

AU - Fabrizi, Fabrizio

AU - Martin, Paul

PY - 2006/12/1

Y1 - 2006/12/1

N2 - PURPOSE OF REVIEW: The management of hepatitis B and C-related liver disease in patients with chronic kidney disease remains an area of controversy. The availability of novel antiviral agents has allowed the implementation of numerous trials concerning the treatment of hepatitis before and after renal transplantation. RECENT FINDINGS: Long-term trials with lamivudine for chronic hepatitis B infections after renal transplantation have shown durable suppression of hepatitis B viraemia ranging between 43 and 78%; however, the 3-4 year cumulative probability of developing lamivudine resistance is approximately 60%. Lamivudine-resistant strains have led to hepatic decompensation in several renal transplant recipients. The sustained virological response rate after interferon monotherapy in dialysis patients with chronic hepatitis C is approximately 40%, but tolerance to interferon monotherapy is poor, and its use is contraindicated after renal transplantation because of acute graft dysfunction. Encouraging sustained virological responses have been obtained after combined therapy (interferon plus ribavirin) in dialysis patients, but the appropriate ribavirin dose remains to be assessed. Only preliminary information exists on the use of pegylated interferon in end-stage renal disease. SUMMARY: This review summarizes recent and novel advances in the antiviral treatment of hepatitis B and C in dialysis patients and renal transplant recipients.

AB - PURPOSE OF REVIEW: The management of hepatitis B and C-related liver disease in patients with chronic kidney disease remains an area of controversy. The availability of novel antiviral agents has allowed the implementation of numerous trials concerning the treatment of hepatitis before and after renal transplantation. RECENT FINDINGS: Long-term trials with lamivudine for chronic hepatitis B infections after renal transplantation have shown durable suppression of hepatitis B viraemia ranging between 43 and 78%; however, the 3-4 year cumulative probability of developing lamivudine resistance is approximately 60%. Lamivudine-resistant strains have led to hepatic decompensation in several renal transplant recipients. The sustained virological response rate after interferon monotherapy in dialysis patients with chronic hepatitis C is approximately 40%, but tolerance to interferon monotherapy is poor, and its use is contraindicated after renal transplantation because of acute graft dysfunction. Encouraging sustained virological responses have been obtained after combined therapy (interferon plus ribavirin) in dialysis patients, but the appropriate ribavirin dose remains to be assessed. Only preliminary information exists on the use of pegylated interferon in end-stage renal disease. SUMMARY: This review summarizes recent and novel advances in the antiviral treatment of hepatitis B and C in dialysis patients and renal transplant recipients.

KW - Interferon

KW - Lamivudine

KW - Renal transplantation

KW - Ribavirin

KW - Sustained virological response

UR - http://www.scopus.com/inward/record.url?scp=33751211857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751211857&partnerID=8YFLogxK

U2 - 10.1097/MOT.0b013e3280105c5c

DO - 10.1097/MOT.0b013e3280105c5c

M3 - Article

VL - 11

SP - 583

EP - 588

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 6

ER -